 AUSTIN, TX and DURHAM, NC, Nov. 11, 2020 GLOBE NEWSWIRE -- Shattuck Labs, Inc. Shattuck NASDAQ: STTK, a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the presentation of preclinical data from its Gamma Delta T Cell Engager, or GADLENTM, platform. The presentation, titled In vivo expansion of gamma delta T cells by a CD19-targeted butyrophilin heterodimer leads to elimination of peripheral B cells, will be presented by Suresh de Silva, Ph.D., VP of Product Development at Shattuck, at the Society for Immunotherapy of Cancers SITC 35th Anniversary Annual Meeting, which is being held virtually November 9-14, 2020. The GADLEN platform is a novel class of bi-functional fusion proteins that are T cell engager molecules targeting gamma delta T cells to kill tumor cells expressing specific tumor antigens. 